Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity.
Limited data are available on cognitive performance in populations of intravenous drug users during the early, asymptomatic stages of human immunodeficiency virus type 1 (HIV-1) infection. Between 1988 and 1990, 151 participants from the AIDS Link to Intravenous Experience (ALIVE) Study in Baltimore, Maryland, were evaluated neuropsychologically on a semiannual basis. This analysis focused on whether history of substance abuse influenced neuropsychological test performance. At baseline, 102 participants were HIV-1-seropositives who were free of acquired immunodeficiency syndrome and 49 participants were seronegative. Multivariate analyses, adjusting for correlation of repeated outcome measures, were conducted to determine predictors of neuropsychological functioning. Effects of the frequency of reported past use of marijuana, heroin, cocaine, barbiturates, and alcohol were not statistically associated with performance on the tests. Age and education were the most important predictors of test performance, and a significant practice effect was observed for most measures. After adjustment for age, education, the practice effect, and frequency of drug use, neuropsychological performance over time did not vary by HIV-1 serostatus. Overall, after acutely intoxicated individuals were excluded, neither frequency of drug and alcohol use nor HIV-1 seropositivity significantly influenced neuropsychological test performance over a 1-year period.
Concha
M
M
Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD.
Graham
N M
NM
Muñoz
A
A
Vlahov
D
D
Royal
W
W
Updike
M
M
Nance-Sproson
T
T
Selnes
O A
OA
McArthur
J C
JC
D000328:Adult; D001741:Black or African American; D000367:Age Factors; D015142:Baltimore / Q000453:epidemiology; D015496:CD4-Positive T-Lymphocytes; D002908:Chronic Disease; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D015986:Confounding Factors, Epidemiologic; D004522:Educational Status; D004651:Employment / Q000706:statistics & numerical data; D005069:Evaluation Studies as Topic; D005260:Female; D006679:HIV Seropositivity / Q000097:blood / Q000150:complications*; D015528:HIV Seroprevalence; D015497:HIV-1; D006801:Humans; D007958:Leukocyte Count; D016014:Linear Models; D008297:Male; D008403:Mass Screening; D009483:Neuropsychological Tests; D011159:Population Surveillance; D011237:Predictive Value of Tests; D011330:Prisons / Q000706:statistics & numerical data; D011597:Psychomotor Performance; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000628:therapy